China Introduces First CAR T Therapy for Solid Tumors
Published: 08 Jul 2026
Author: Vidyesh Swar
In April 2026, a new CAR-T cell therapy targeting advanced gastrointestinal cancers is anticipated to become available in China, as reported by the Jiahui International Cancer Center. This institution is set to lead in offering access to the therapy known as satri-cel (CT041), which is recognized as the world’s first CAR-T treatment specifically formulated for solid tumors that target Claudin18.2, a biomarker prevalent in gastric and pancreatic cancers.
A new CAR-T cell therapy addresses a significant unmet medical need
The advent of this CAR-T therapy addresses a significant unmet medical need. Advanced gastric and pancreatic cancers represent some of the most formidable challenges in oncology, characterized by limited effective options in later lines of treatment and suboptimal survival rates. This novel CAR-T therapy introduces an alternative treatment avenue for patients who have exhausted conventional options.
This development marks a crucial milestone in oncological treatment, potentially extending the application of CAR-T therapies beyond hematological cancers to solid tumors. According to the Jiahui International Cancer Center, ongoing research is actively investigating the broader applicability of this therapy, including treatment for earlier stages of cancer and various tumor types.
Industry Impact and Market Outlook
The global CAR T-cell therapy market size is calculated at USD 5,206.15 million in 2025 and is predicted to increase from USD 6,0836.15 million in 2026 to approximately USD 26,982.3 million by 2035, expanding at a CAGR of 17.88% from 2026 to 2035. This growth is due to rising prevalence of cancer, demand for personalized medicine and FDA approvals for new therapies.
Unlike traditional therapies, CAR-T cells possess the ability to proliferate within the body, sustaining their fight against cancer over time. While CAR-T advancements have already transformed outcomes in blood cancers, this groundbreaking therapy signifies notable progress in addressing solid tumors, where effective treatments have historically been sparse.